This discussion focuses on how mRNA and self-replicating RNA (srRNA) technologies are expanding far beyond COVID vaccines into revolutionary therapeutic applications for cancer and rare diseases. It is clear that mRNA therapeutics offer three major application areas: infectious disease vaccines, therapeutic vaccines for oncology, and protein replacement for monogenic rare diseases.
Today’s episode is sponsored by Eclipsebio. From AI-ready datasets to sequencing validation, they drive RNA success.
Explore their solutions at https://eclipsebio.com/.
Host
Lori Ellis, Head of Insights, BioSpace
Guests
Andy Geall, Co-founder and Chief Development Officer, Replicate Bioscience; Chair of the Board, Alliance for mRNA Medicines
Pad Chivukula, Co-founder, CSO & COO, Arcturus Therapeutics
Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.